Patents by Inventor Richard P. Phipps
Richard P. Phipps has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11400057Abstract: The present invention relates to methods of treating female reproductive tract irritation (such as pain and pruritus) or/and inflammation.Type: GrantFiled: October 2, 2019Date of Patent: August 2, 2022Assignee: University of RochesterInventors: David Foster, Megan L. Falsetta Wood, Richard P. Phipps
-
Publication number: 20220040136Abstract: The present invention relates to methods of treating vulvovaginal disorders, including female reproductive tract irritation (such as pain and pruritus) or/and inflammation.Type: ApplicationFiled: October 2, 2019Publication date: February 10, 2022Inventors: David FOSTER, Megan L. FALSETTA WOOD, Richard P. PHIPPS
-
Publication number: 20200121617Abstract: The present invention relates to methods of treating female reproductive tract irritation (such as pain and pruritus) or/and inflammation.Type: ApplicationFiled: October 2, 2019Publication date: April 23, 2020Applicant: University of RochesterInventors: David Foster, Megan L. Falsetta Wood, Richard P. Phipps
-
Patent number: 10548911Abstract: Disclosed are methods of treating fibrosis in a patient in need thereof that includes administering to the patient an amount of an active agent, as identified herein, that is therapeutically effective to inhibit myofibroblast formation and thereby treat the fibrosis. Also disclosed is a recombinant cell line that includes a recombinant gene that expresses a detectable expression product in a dose-dependent response to TGF?, as well as methods of identifying a compound that inhibits TGF?-mediated expression of the detectable expression product.Type: GrantFiled: June 16, 2015Date of Patent: February 4, 2020Assignee: University of RochesterInventors: Richard P. Phipps, Collynn Woeller
-
Patent number: 10285794Abstract: An improved abdominal hernia repair system is presented comprised of a silicone layer backed up with a knitted or woven polypropylene fabric layer, the silicone layer possessing a regular pattern of slits that permit equilibration of fluid pressure across the device. A variety of therapeutic substances can be applied to the hernia repair device to promote healing, including aloe and other medicinal preparations. A layer of water soluble or water insoluble anti-scar compound is also present, the preferred compound being Salinomycin. An improved inguinal hernia repair system is presented that is identical to the above except it does not contain the hydrophobic silicone component.Type: GrantFiled: March 6, 2017Date of Patent: May 14, 2019Inventors: E. Aubrey Woodroof, Richard P. Phipps, Collyn F. Woeller, Lipton Laverne Martin
-
Publication number: 20170281326Abstract: An improved abdominal hernia repair system is presented comprised of a silicone layer backed up with a knitted or woven polypropylene fabric layer, the silicone layer possessing a regular pattern of slits that permit equilibration of fluid pressure across the device. A variety of therapeutic substances can be applied to the hernia repair device to promote healing, including aloe and other medicinal preparations. A layer of water soluble or water insoluble anti-scar compound is also present, the preferred compound being Salinomycin. An improved inguinal hernia repair system is presented that is identical to the above except it does not contain the hydrophobic silicone component.Type: ApplicationFiled: March 6, 2017Publication date: October 5, 2017Inventors: E. Aubrey Woodroof, Richard P. Phipps, Collyn F. Woeller, Lipton Laverne Martin
-
Patent number: 9750749Abstract: The present invention relates to a methods and compositions for the treatment of and management of symptoms for thyroid eye disease. The methods include administering to a patient having thyroid eye disease an agent that interferes with hyaluronan synthesis in an amount that is effective to inhibit hyaluronan synthesis in a retro-ocular space. The pharmaceutical compositions that includes a carrier suitable for ophthalmic delivery and an agent that interferes with hyaluronan synthesis. Combination therapies are also disclosed.Type: GrantFiled: March 4, 2016Date of Patent: September 5, 2017Assignee: University of RochesterInventors: Richard P. Phipps, Naxin Guo, Steven Feldon
-
Patent number: 9750761Abstract: One aspect of the disclosure relates to methods of treating a fibrotic condition in an individual. The methods include administering to an individual having a fibrotic condition an effective amount of a lactic dehydrogenase (LDH) inhibitor, wherein the fibrotic condition involves an internal organ or tissue, or ocular tissue, and said administering is effective to treat the fibrotic condition. Methods of administration and pharmaceutical compositions and systems for practicing such methods are also disclosed.Type: GrantFiled: May 21, 2015Date of Patent: September 5, 2017Assignee: University of RochesterInventors: Robert M. Kottmann, Patricia J. Sime, Richard P. Phipps
-
Publication number: 20170216332Abstract: Disclosed are methods of treating fibrosis in a patient in need thereof that includes administering to the patient an amount of an active agent, as identified herein, that is therapeutically effective to inhibit myofibroblast formation and thereby treat the fibrosis. Also disclosed is a recombinant cell line that includes a recombinant gene that expresses a detectable expression product in a dose-dependent response to TGF?, as well as methods of identifying a compound that inhibits TGF?-mediated expression of the detectable expression product.Type: ApplicationFiled: June 16, 2015Publication date: August 3, 2017Applicant: UNIVERSITY OF ROCHESTERInventors: Richard P. Phipps, Collynn Woeller
-
Patent number: 9694050Abstract: The present invention relates to methods of treating a condition involving excessive adipogenesis. This method relates to selecting a subject having a condition involving excessive adipogenesis and administering to the selected subject a composition comprising a Thy1 protein or polypeptide fragment thereof, or an agent that enhances Thy1 expression, under conditions effective to treat the condition. The present invention also relates to isolated nucleic acid molecules encoding a Thy1 protein or the fragment thereof and pharmaceutical formulations including such a protein or fragment thereof or an agent that enhances Thy1 expression and a pharmaceutically acceptable carrier. The present invention also relates to methods of inhibiting adipogenesis and/or decreasing adipocyte size, as well as methods of screening a candidate compound for its ability to influence adipogenesis.Type: GrantFiled: October 21, 2013Date of Patent: July 4, 2017Assignee: University of RochesterInventors: Richard P. Phipps, Collynn F. Woeller, Steven E. Feldon
-
Publication number: 20160199386Abstract: The present invention relates to a methods and compositions for the treatment of and management of symptoms for thyroid eye disease. The methods include administering to a patient having thyroid eye disease an agent that interferes with hyaluronan synthesis in an amount that is effective to inhibit hyaluronan synthesis in a retro-ocular space. The pharmaceutical compositions hat includes a carrier suitable for ophthalmic delivery and an agent that interferes with hyaluronan synthesis. Combination therapies are also disclosed.Type: ApplicationFiled: March 4, 2016Publication date: July 14, 2016Applicant: University of RochesterInventors: Richard P. Phipps, Naxin Guo, Steven Feldon
-
Patent number: 9320723Abstract: The present invention relates to a methods and compositions for the treatment of and management of symptoms for thyroid eye disease. The methods include administering to a patient having thyroid eye disease an agent that interferes with hyaluronan synthesis in an amount that is effective to inhibit hyaluronan synthesis in a retro-ocular space. The pharmaceutical compositions hat includes a carrier suitable for ophthalmic delivery and an agent that interferes with hyaluronan synthesis. Combination therapies are also disclosed.Type: GrantFiled: May 3, 2011Date of Patent: April 26, 2016Assignee: University of RochesterInventors: Richard P. Phipps, Naxin Guo, Steven Feldon
-
Publication number: 20150335674Abstract: One aspect of the disclosure relates to methods of treating a fibrotic condition in an individual. The methods include administering to an individual having a fibrotic condition an effective amount of a lactic dehydrogenase (LDH) inhibitor, wherein the fibrotic condition involves an internal organ or tissue, or ocular tissue, and said administering is effective to treat the fibrotic condition. Methods of administration and pharmaceutical compositions and systems for practicing such methods are also disclosed.Type: ApplicationFiled: May 21, 2015Publication date: November 26, 2015Applicant: UNIVERSITY OF ROCHESTERInventors: Robert M. Kottmann, Patricia J. Sime, Richard P. Phipps
-
Publication number: 20150283205Abstract: The present invention relates to methods of treating a condition involving excessive adipogenesis. This method relates to selecting a subject having a condition involving excessive adipogenesis and administering to the selected subject a composition comprising a Thy1 protein or polypeptide fragment thereof, or an agent that enhances Thy1 expression, under conditions effective to treat the condition. The present invention also relates to isolated nucleic acid molecules encoding a Thy1 protein or the fragment thereof and pharmaceutical formulations including such a protein or fragment thereof or an agent that enhances Thy1 expression and a pharmaceutically acceptable carrier. The present invention also relates to methods of inhibiting adipogenesis and/or decreasing adipocyte size, as well as methods of screening a candidate compound for its ability to influence adipogenesis.Type: ApplicationFiled: October 21, 2013Publication date: October 8, 2015Applicant: University of RochesterInventors: Richard P. PHIPPS, Collynn F. WOELLER, Steven E. FELDON
-
Publication number: 20150265629Abstract: The present invention is directed to a method of inducing platelet production that includes contacting a megakaryocyte with an electrophilic compound under conditions effective to induce platelet production by the contacting megakaryocyte. Methods of treating a patient for low platelet levels, increasing the circulating half-life of platelets, and improving the quality (activity) of platelets are also disclosed herein, which involve administering the electrophilic compound to a patient an effective amount to achieve the desired effect. Pharmaceutical compositions and therapeutic systems are also disclosed for carrying out these therapeutic treatments.Type: ApplicationFiled: April 20, 2015Publication date: September 24, 2015Applicant: UNIVERSITY OF ROCHESTERInventors: Richard P. Phipps, Jamie J. Bernard
-
Patent number: 9012439Abstract: The present invention is directed to a method of inducing platelet production that includes contacting a megakaryocyte with an electrophilic compound under conditions effective to induce platelet production by the contacting megakaryocyte. Methods of treating a patient for low platelet levels, increasing the circulating half-life of platelets, and improving the quality (activity) of platelets are also disclosed herein, which involve administering the electrophilic compound to a patient an effective amount to achieve the desired effect. Pharmaceutical compositions and therapeutic systems are also disclosed for carrying out these therapeutic treatments.Type: GrantFiled: October 29, 2008Date of Patent: April 21, 2015Assignee: University of RochesterInventors: Richard P. Phipps, Jamie O'Brien
-
Publication number: 20120015001Abstract: The present invention relates to a methods and compositions for the treatment of and management of symptoms for thyroid eye disease. The methods include administering to a patient having thyroid eye disease an agent that interferes with hyaluronan synthesis in an amount that is effective to inhibit hyaluronan synthesis in a retro-ocular space. The pharmaceutical compositions hat includes a carrier suitable for ophthalmic delivery and an agent that interferes with hyaluronan synthesis. Combination therapies are also disclosed.Type: ApplicationFiled: May 3, 2011Publication date: January 19, 2012Applicant: UNIVERSITY OF ROCHESTERInventors: Richard P. Phipps, Naxin Guo, Steven Feldon
-
Publication number: 20110300129Abstract: Pharmaceutical compositions of the invention include an antigen or a nucleic acid molecule encoding the antigen; one or both of a PPAR ligand and an RxR ligand; and a pharmaceutically suitable carrier. The pharmaceutical composition can optionally include a mitogen or other additives. Also disclosed are methods of inducing B cell differentiation and promoting an immune response against an antigen.Type: ApplicationFiled: December 14, 2009Publication date: December 8, 2011Applicant: UNIVERSITY OF ROCHESTERInventors: Richard P. Phipps, Tatiana Margarita Garcia-Bates
-
Publication number: 20110027223Abstract: The present invention is directed to a method of inducing platelet production that includes contacting a megakaryocyte with an electrophilic compound under conditions effective to induce platelet production by the contacting megakaryocyte. Methods of treating a patient for low platelet levels, increasing the circulating half-life of platelets, and improving the quality (activity) of platelets are also disclosed herein, which involve administering the electrophilic compound to a patient an effective amount to achieve the desired effect. Pharmaceutical compositions and therapeutic systems are also disclosed for carrying out these therapeutic treatments.Type: ApplicationFiled: October 29, 2008Publication date: February 3, 2011Applicant: UNIVERSITY OF ROCHESTERInventors: Richard P. Phipps, Jamie O'Brien
-
Patent number: 7384639Abstract: The present invention relates to an immunogenic conjugate comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria The immunogenic conjugate, when combined with a pharmaceutically acceptable carrier, forms a suitable vaccine for mammals to prevent infection by the Gram negative bacteria The immunogenic conjugate is also used to raise and subsequently isolate antibodies or binding portions thereof which are capable of recognizing and binding to the autoinducer. The antibodies or binding portions thereof are utilized in a method of treating infections, a method of inhibiting autoinducer activity, and in diagnostic assays which detect the presence of autoinducers or autoinducer antagonists in fluid or tissue samples.Type: GrantFiled: September 6, 2005Date of Patent: June 10, 2008Assignee: University of RochesterInventors: Andrew S. Kende, Barbara H. Iglewski, Roger Smith, Richard P. Phipps, James P. Pearson